Feasibility of Surgery for Advanced NSCLC Treated with Tyrosine Kinase Inhibitors as Neoadjuvant Therapy

Wei-Ciao Wu, Yau-Lin Tseng, Yi-Ting Yen, Wu-Wei Lai

Research output: Contribution to journalArticle

Abstract

The role of surgical resection after tyrosine-kinase inhibitor (TKI) treatment in locally advanced NSCLC remains controversial. There have benn scanty case reports of successful treatment outcome resulting from complete resection post-TKI response. However, there is no consensus on indication or timing of surgical resection in locally advanced NSCLC treated with TKIs. We present the cases of 10 patients with NSCLC stage IIIa~VI who received TKIs as first-line treatment. Surgical resection was performed in various situations, including those in which complete resection could be achieved and those in which the patient could not withstand the adverse effects of TKI. Surgical outcomes and survival patterns were acceptable. TKIs can be used as neoadjuvant therapy, but further research should indicate the timing of surgery and the criteria of patient selection. We believe future clinical trial should be conducted to evaluate this treatment modality.
Original languageEnglish
Pages (from-to)236-242
Number of pages7
Journal胸腔醫學
Volume31
Issue number4
Publication statusPublished - 2016
Externally publishedYes

Keywords

  • 酪氨酸激酶抑制劑
  • 前導治療
  • 非小細胞肺癌
  • tyrosine kinase inhibitor
  • neoadjuvant
  • non small cell lung cancer

Fingerprint Dive into the research topics of 'Feasibility of Surgery for Advanced NSCLC Treated with Tyrosine Kinase Inhibitors as Neoadjuvant Therapy'. Together they form a unique fingerprint.

  • Cite this